- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02231060
Study for the Improvement of Long-Term Outcome Prediction in Patients in Coma After Cardiac Arrest (HOPE)
Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors
Study Overview
Status
Conditions
Detailed Description
HOPE conducts a 2.5-year multicenter prospective cohort study in Germany on outcome prediction in the early stages of coma caused by cerebral hypoxia-ischemia.
The main features of the project are:
- Control for a self-fulfilling prophecy
- Long-term follow-up (12 months) covering acute and neurorehabilitation phases
- Use of sensitive measures of level of consciousness
- Further in-depth and systematic examination of the predictive value of somato-sensory evoked potentials (SSEP)
Using as a reference existing guidelines and previous research, we consider the following factors to be predictors of a negative outcome with a high specificity of > 90% with small 95% confidence intervals: loss of cortical N20 SEP potentials, loss of more than one brain stem reflex, non-reactive EEG, or a NSE above 33 mcg/L. We refer to the presence of any of these specific unfavourable test results during the ICU treatment as a "negative predictor". Therefore, our null hypothesis is that the probability of a favourable outcome, despite the presence of a negative predictor, is < 10%. We will use Simon's two-stage design. The null hypothesis will be tested against a one-sided alternative. In the first stage, we will accrue 72 patients. If there are 8 or fewer good outcomes in these 72 patients, the study will be discontinued because the null hypothesis could not be rejected. Otherwise, we will recruit 100 additional patients to gather a total of 172. The null hypothesis will be rejected if 28 or more favourable outcomes are observed in these 172 patients. This design yields a type I error rate of 0.05 and power of 80% if the true response rate is 25%, i.e. if indeed 25% or more patients have a favourable outcome despite a negative predictor. This calculation is based on the assumption that 25% of the enrolled patients have at least one negative predictor.
HOPE has seven data entry points (i.e. study visits).The primary endpoints are completion of the follow-up period or patient death. HOPE collects clinical and demographic data in accordance to Utstein-style recommendations. The most crucial part of the study is determining the current level of consciousness by means of the revised version of the Coma Recovery Scale (CRS-R). The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions. Other assessment instruments employed yield information about functional outcome/ADL, neuropsychological performance, and health-related quality of life.
Study centers will collect data prospectively following a data acquisition timeline (e.g. t0 to t6). Visits t0 to t2 will take place at acute-setting ICUs; visits t3 to t5 at neurorehabilitation centers; and visit t6 at the patients' location of residence 12 months after day 0. A manual and data dictionary will be provided to all centres along with the case report forms (CRF). All study centers will send pseudonymized data weekly by certified mail to the Central Study Centre (CSC) located at the Department of Neurology of the University of Munich. All study centres, including the CSC, will check the data for completeness, plausibility, accuracy, consistency and outliers. Legal representatives of coma patients, who decline to participate, will be asked to provide data on socio-demographic variables and reason for declining. The CSC will store the data at a database and will be responsible for safeguarding and analysing it. Patients/Legal representatives will be asked to remain in the study for a further follow-up. After completion of the follow-up period, datasets will be irreversibly anonymised.
We will analyze the positive predictive value of a dichotomous prognostic marker (favorable or unfavourable SSEP). For this purpose, we will use two definitions of favorable outcome, i.e. a functional and a behavioral one. If outcome is defined with respect to independence in daily life, we will use a modified Rankin Scale score of 0-3 (no symptoms - moderate disability, but able to walk independently) to categorize a favorable functional outcome. In the context of a catastrophic event such as cardiac arrest with high likelihood of permanent VS, it is our experience that some patients and families consider regaining functional communications skills also a favourable outcome. In a separate analysis, we will therefore use the recovery of full consciousness as measured by the CRS-R to define a favorable behavioral outcome. To analyse the effect of covariates on functional and behavioral outcomes, we will use mixed effects regression models, including both fixed and random effects. This method of analyzing longitudinal data is highly effective to examine change trajectories with several unequally spaced waves of data. Covariates will be sociodemographic variables, prognostic variables and treatment factors (e.g. use of therapeutic hypothermia), adjusted for age and sex.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Bavaria
-
Bad Tölz, Bavaria, Germany, 83646
- Dept of Neurology, Asklepios Stadtklinik Bad Tölz
-
Munich, Bavaria, Germany, D-81377
- Clinic for Anesthesiology, University of Munich
-
-
Bayern
-
Augsburg, Bayern, Germany, 86009
- Department of Neurology, Klinikum Augsburg
-
Augsburg, Bayern, Germany, 86009
- I. Medizinische Klinik, Klinikum Augsburg
-
Bad Aibling, Bayern, Germany, 83043
- Schön Klinik Bad Aibling
-
Burgau, Bayern, Germany, 89331
- Therapiezentrum Burgau
-
Ingolstadt, Bayern, Germany, 85021
- Medizinische Klinik I und IV, Klinikum Ingolstadt
-
Ingolstadt, Bayern, Germany, 85021
- Neurologische Klinik, Klinikum Ingolstadt
-
Munich, Bayern, Germany, 81377
- Department of Neurology, University of Munich
-
Munich, Bayern, Germany, 80636
- Deutsches Herzzentrum Muenchen
-
Munich, Bayern, Germany, 80639
- Krankenhaus Barmherzige Brüder München
-
Munich, Bayern, Germany, 80804
- Schön Klinik München Schwabing
-
Munich, Bayern, Germany, 81377
- Internal ICU, Medical Clinic and Polyclinic IV, University of Munich
-
Munich, Bayern, Germany, 81377
- Medizinische Klinik und Poliklinik I, University of Munich
-
Munich, Bayern, Germany, 81675
- Department of Neurology
-
Rosenheim, Bayern, Germany, 83022
- Neurologische Klinik, RoMed Klinikum Rosenheim
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 18 and 85 years
- Cause of admission to ICU: cardiac arrest (in or out of hospital)
- Glasgow-Coma-Scale < 9 at time of study enrolment (3 to 8 days after cardiac arrest)
- Informed consent signed by legal guardian/next-of-kin
Exclusion Criteria:
- Stroke (as it may interfere with SSEP testing)
- Pre-existing coma/vegetative state/minimally conscious state
- Terminal malignant disease
- Survival in the next 12 months extremely unlikely
- Existing advanced directive that demands cessation of therapy/life support
- Palliative care/withdrawal of life support during treatment at the ICU
- Barbiturate-induced general anesthesia during the first 3 days after cardiac arrest
- Impossibility of assessing current level of consciousness with the Glasgow Coma Scale due to a long-term deep sedation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
AIE after Cardiac Arrest
Male and female patients with AIE following CA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Current level of consciousness as measured by the revised version of the Coma Recovery Scale (CRS-R)
Time Frame: There are 6 CRS-R data entry points distributed within a 12-month period, namely, 2 time points at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
|
The CRS-R allows a precise categorization of the current level of consciousness based on a structured and systematic clinical examination of auditory, visual, motor, oromotor, communication and arousal functions.
|
There are 6 CRS-R data entry points distributed within a 12-month period, namely, 2 time points at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Regaining of functional communication skills and optimal health-related quality of life
Time Frame: Five data entry points distributed within a 12-month period, namely, 1 time point at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
|
Five data entry points distributed within a 12-month period, namely, 1 time point at the ICU, 3 time points during neurorehabilitation and 1 time point at the patient's residence 12 months after day 0.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andreas Bender, MD, Ludwig-Maximilians-Universität München
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014_A55
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anoxic-Ischemic Encephalopathy
-
Hospices Civils de LyonCompletedAnoxic-Ischemic EncephalopathyFrance
-
Radboud University Medical CenterUnknownCardiac Arrest | Post-Anoxic EncephalopathyNetherlands
-
University of California, San FranciscoThe ZOLL FoundationRecruitingSeizures | Heart Arrest | Hypoxia-Ischemia, Brain | Status Epilepticus | Refractory Status Epilepticus | Anoxic-Ischemic Encephalopathy | Anoxia-Ischemia, CerebralUnited States
-
University of PennsylvaniaCompletedIschemic Stroke | Traumatic Brain Injury | Subarachnoid Hemorrhage | Intracerebral Hemorrhage | Acute Anoxic EncephalopathyUnited States
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Sajjad RahmanUnknownSevere Hypoxic Ischemic Encephalopathy | Moderate Hypoxic Ischemic EncephalopathyTurkey, Egypt, Malaysia, Qatar, Saudi Arabia, United Arab Emirates
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedHypoxia, Brain | Hypoxia-Ischemia, Brain | Hypoxic-Ischemic Encephalopathy | Infant, Newborn | Ischemic-Hypoxic Encephalopathy | Encephalopathy, Hypoxic-IschemicUnited States
-
Johns Hopkins UniversityUniversity of MarylandCompletedEncephalopathy, Hypoxic-IschemicUnited States
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsCompletedNeonatal Encephalopathy | Hypoxic-ischemic EncephalopathyJapan
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsUnknownNeonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)Japan